Movement Disorders

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-04-24
EMA Authorised: Striascan (ioflupane (123l)) — CIS bio international
The EMA authorised Striascan (ioflupane (123I)) from CIS bio international for radionuclide imaging in dementia and movement disorders, with…